2,161 Shares in Johnson & Johnson (NYSE:JNJ) Purchased by Sherrill & Hutchins Financial Advisory Inc

Sherrill & Hutchins Financial Advisory Inc acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,161 shares of the company’s stock, valued at approximately $339,000. Johnson & Johnson comprises approximately 0.3% of Sherrill & Hutchins Financial Advisory Inc’s portfolio, making the stock its 10th biggest holding.

Other hedge funds have also modified their holdings of the company. Hibernia Wealth Partners LLC acquired a new position in Johnson & Johnson in the third quarter valued at $27,000. FNY Investment Advisers LLC acquired a new position in shares of Johnson & Johnson in the 3rd quarter valued at about $37,000. Tower View Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 183.3% during the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after acquiring an additional 165 shares in the last quarter. Creative Capital Management Investments LLC increased its holdings in Johnson & Johnson by 43.0% in the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock valued at $45,000 after purchasing an additional 86 shares in the last quarter. Finally, VitalStone Financial LLC purchased a new position in Johnson & Johnson in the second quarter valued at about $48,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Morgan Stanley dropped their target price on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 24th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Raymond James increased their target price on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, March 13th. Finally, Wells Fargo & Company downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $170.00 to $163.00 in a research report on Wednesday, December 13th. Seven analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $177.31.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $157.96 on Thursday. The firm has a market capitalization of $380.65 billion, a PE ratio of 11.44, a P/E/G ratio of 2.62 and a beta of 0.53. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. The firm has a 50-day moving average price of $158.76 and a 200 day moving average price of $156.69. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $175.97.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. The business had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The business’s revenue for the quarter was down 9.7% on a year-over-year basis. During the same quarter last year, the business earned $2.35 earnings per share. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 5th. Stockholders of record on Tuesday, February 20th were issued a $1.19 dividend. The ex-dividend date of this dividend was Friday, February 16th. This represents a $4.76 annualized dividend and a dividend yield of 3.01%. Johnson & Johnson’s dividend payout ratio (DPR) is 34.47%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.